Medtronic’s CoreValve as good as surgery in intermediate-risk trial
A study comparing surgical valve replacement with transcatheter aortic valve replacement using the CoreValve device made by Medtronic (NYSE:MDT) showed that the TAVR device was as safe as surgery in intermediate-risk patients, according to data presented today at ACC 2017.
Two-year data from the 1,657-patient Surtavi study, presented at ACC 2017 and published in the New England Journal of Medicine, showed non-inferiority for the CoreValve implant for an endpoint combining all-cause mortality and disabling stroke, with the TAVR device showing a 12.6% rate compared with 14% for surgical intervention. The rate of death was 11.4% for TAVR and 11.6% for surgery; the rate of disabling stroke was 2.6% for the TAVR cohort and 4.5% for the control group.
